Novartis drug pasireotide LAR shows superior efficacy compared to Sandostatin® LAR® in Phase III trial of patients with acromegaly
7 May 2012 | By Novartis
Results of the largest Phase III study...
List view / Grid view
7 May 2012 | By Novartis
Results of the largest Phase III study...
2 May 2012 | By Novartis
Definitive agreement to acquire Fougera Pharmaceuticals for USD 1.525 billion in an all-cash transaction...
1 May 2012 | By Novartis
Results from two-year CATT...
26 April 2012 | By Novartis
The FDA has approved Afinitor® tablets...
26 April 2012 | By Novartis
Novartis associates to dedicate 200,000 work hours to supporting the local community...
25 April 2012 | By Novartis
Novartis announced that the European Commission has approved Signifor®...
20 April 2012 | By Novartis
Upon approval, Jakavi(TM) (INC424, ruxolitinib) will be the first EU approved JAK inhibitor developed to treat patients with myelofibrosis, a rare blood cancer...
2 April 2012 | By Novartis
QVA149 efficacy, safety and exercise endurance primary endpoints all met[1],[2],[3]...
28 March 2012 | By Novartis
Collaboration with the Broad Institute yields comprehensive encyclopedia of genetic and molecular information...
16 March 2012 | By Novartis
Potential first pharmacological treatment for symptomatic vitreomacular adhesion...
7 March 2012 | By Novartis
A study found that the investigational drug Signifor®, normalized cortisol levels...
29 February 2012 | By Novartis
Novartis named Brian McNamara to the position of Division Head of Novartis OTC (Over-the-Counter), effective immediately...
29 February 2012 | By Novartis
Results of the COMFORT-I and COMFORT-II trials show INC424 significantly reduced disease burden in patients with myelofibrosis...
27 February 2012 | By Novartis
The European Commission has approved an update to the Glivec® (imatinib)* label...
17 February 2012 | By Novartis
CHMP concluded the risk-benefit review of Rasilez* (aliskiren)...